Evotec SE (WBO:EVT) Debt-to-Equity : 0.56 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Debt-to-Equity?

Evotec SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €149.1 Mil. Evotec SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €477.1 Mil. Evotec SE's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €1,119.9 Mil. Evotec SE's debt to equity for the quarter that ended in Dec. 2023 was 0.56.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Evotec SE's Debt-to-Equity or its related term are showing as below:

WBO:EVT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.39 Max: 1.03
Current: 0.52

During the past 13 years, the highest Debt-to-Equity Ratio of Evotec SE was 1.03. The lowest was 0.03. And the median was 0.39.

WBO:EVT's Debt-to-Equity is ranked worse than
67.64% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs WBO:EVT: 0.52

Evotec SE Debt-to-Equity Historical Data

The historical data trend for Evotec SE's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Debt-to-Equity Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.97

0.68

0.37

0.43

0.56

Evotec SE Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.40	0.43	-	0.52	0.56

Competitive Comparison of Evotec SE's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Evotec SE's Debt-to-Equity falls into.

Evotec SE Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Evotec SE's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(149.096	+	477.112)	/	1119.907
	=	0.56

Evotec SE's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(149.096	+	477.112)	/	1119.907
	=	0.56

Evotec SE (WBO:EVT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Evotec SE Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Evotec SE's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (WBO:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines

From GuruFocus

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023